• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Elevated neutralization of Omicron with sera of COVID-19 recovered and breakthrough cases vaccinated with Covaxin than two dose naïve vaccinees.

作者信息

Yadav Pragya D, Sapkal Gajanan N, Sahay Rima R, Patil Deepak Y, Deshpande Gururaj R, Jain Rajlaxmi, Nyayanit Dimpal A, Shete Anita M, Suryawanshi Annasaheb, Nandapurkar Ashok, Gurav Yogesh K, Abraham Priya

机构信息

Indian Council of Medical Research-National Institute of Virology, Pune 411021, India.

Indian Council of Medical Research-National Institute of Virology, Pune 411021, India.

出版信息

J Infect. 2022 Jun;84(6):834-872. doi: 10.1016/j.jinf.2022.03.016. Epub 2022 Mar 19.

DOI:10.1016/j.jinf.2022.03.016
PMID:35318093
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8934181/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/db1c/8934181/3ff9ea699f6e/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/db1c/8934181/dde55de56865/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/db1c/8934181/3ff9ea699f6e/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/db1c/8934181/dde55de56865/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/db1c/8934181/3ff9ea699f6e/gr2_lrg.jpg

相似文献

1
Elevated neutralization of Omicron with sera of COVID-19 recovered and breakthrough cases vaccinated with Covaxin than two dose naïve vaccinees.与仅接种两剂疫苗的未感染过新冠病毒的人群相比，新冠康复者和接种Covaxin疫苗后出现突破性感染病例的血清对奥密克戎的中和能力有所提高。
J Infect. 2022 Jun;84(6):834-872. doi: 10.1016/j.jinf.2022.03.016. Epub 2022 Mar 19.
2
Neutralization effect of plasma from vaccinated COVID-19 convalescents on SARS-CoV-2 Omicron variants.接种 COVID-19 康复者血浆对 SARS-CoV-2 奥密克戎变异株的中和效果。
Front Immunol. 2022 Sep 29;13:975533. doi: 10.3389/fimmu.2022.975533. eCollection 2022.
3
Assessment of antibody responses against SARS-CoV-2 in unvaccinated individuals and vaccinees from Omicron-BA.2 infection in Zhaoqing, Guangdong Province, China.评估中国广东省肇庆市未接种疫苗的个体和奥密克戎 BA.2 感染疫苗接种者针对 SARS-CoV-2 的抗体反应。
Virol J. 2022 Nov 25;19(1):197. doi: 10.1186/s12985-022-01912-0.
4
Immunogenicity of convalescent and vaccinated sera against clinical isolates of ancestral SARS-CoV-2, Beta, Delta, and Omicron variants.恢复期和接种疫苗血清对 SARS-CoV-2 原始株、Beta、Delta 和奥密克戎变异株临床分离株的免疫原性。
Med. 2022 Jun 10;3(6):422-432.e3. doi: 10.1016/j.medj.2022.04.002. Epub 2022 Apr 14.
5
Neutralization of Beta and Delta variant with sera of COVID-19 recovered cases and vaccinees of inactivated COVID-19 vaccine BBV152/Covaxin.用 COVID-19 恢复期患者和灭活 COVID-19 疫苗 BBV152/Covaxin 接种者的血清中和 Beta 和 Delta 变异株。
J Travel Med. 2021 Oct 11;28(7). doi: 10.1093/jtm/taab104.
6
Vaccination-infection interval determines cross-neutralization potency to SARS-CoV-2 Omicron after breakthrough infection by other variants.接种-感染间隔时间决定了突破感染其他变体后对 SARS-CoV-2 奥密克戎的交叉中和效力。
Med. 2022 Apr 8;3(4):249-261.e4. doi: 10.1016/j.medj.2022.02.006. Epub 2022 Mar 4.
7
Neutralization sensitivity, fusogenicity, and infectivity of Omicron subvariants.奥密克戎亚变体的中和敏感性、融合性和感染性。
Genome Med. 2022 Dec 29;14(1):146. doi: 10.1186/s13073-022-01151-6.
8
Preclinical evaluation of safety and immunogenicity of a primary series intranasal COVID-19 vaccine candidate (BBV154) and humoral immunogenicity evaluation of a heterologous prime-boost strategy with COVAXIN (BBV152).一种鼻内 COVID-19 候选疫苗（BBV154）的初步临床安全性和免疫原性评估，以及 COVAXIN（BBV152）异源初免-加强策略的体液免疫原性评估。
Front Immunol. 2022 Dec 8;13:1063679. doi: 10.3389/fimmu.2022.1063679. eCollection 2022.
9
Humoral immunity in dually vaccinated SARS-CoV-2-naïve individuals and in booster-vaccinated COVID-19-convalescent subjects.双重接种 SARS-CoV-2 疫苗的个体和接受 COVID-19 康复者加强针接种的个体的体液免疫。
Infection. 2022 Dec;50(6):1475-1481. doi: 10.1007/s15010-022-01817-8. Epub 2022 Apr 11.
10
Exposure to BA.4/5 S protein drives neutralization of Omicron BA.1, BA.2, BA.2.12.1, and BA.4/5 in vaccine-experienced humans and mice.暴露于 BA.4/5 蛋白可导致疫苗接种者体内对奥密克戎 BA.1、BA.2、BA.2.12.1 和 BA.4/5 的中和作用。
Sci Immunol. 2022 Dec 23;7(78):eade9888. doi: 10.1126/sciimmunol.ade9888.

引用本文的文献

1
Neutralizing antibody responses to SARS-CoV-2 Omicron variants: Post six months following two-dose & three-dose vaccination of ChAdOx1 nCoV-19 or BBV152.针对 SARS-CoV-2 奥密克戎变异株的中和抗体反应：接种 ChAdOx1 nCoV-19 或 BBV152 两剂和三剂疫苗后 6 个月。
Indian J Med Res. 2024 Feb 1;159(2):223-231. doi: 10.4103/ijmr.ijmr_948_23. Epub 2024 Apr 4.
2
Broadly Reactive SARS-CoV-2-Specific T-Cell Response and Participation of Memory B and T Cells in Patients with Omicron COVID-19 Infection.广泛反应性的 SARS-CoV-2 特异性 T 细胞应答以及记忆 B 和 T 细胞在奥密克戎 COVID-19 感染患者中的参与。
J Immunol Res. 2023 Oct 17;2023:8846953. doi: 10.1155/2023/8846953. eCollection 2023.
3

本文引用的文献

1
Persistence of immunity and impact of third dose of inactivated COVID-19 vaccine against emerging variants.新冠病毒灭活疫苗第三针接种后免疫持久性及对新型变异株的影响
Sci Rep. 2022 Jul 14;12(1):12038. doi: 10.1038/s41598-022-16097-3.
2
Increased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South Africa.南非出现奥密克戎后，SARS-CoV-2 再感染的风险增加。
Science. 2022 May 6;376(6593):eabn4947. doi: 10.1126/science.abn4947.
3
Antibody titers and breakthrough infections with Omicron SARS-CoV-2.奥密克戎SARS-CoV-2的抗体滴度和突破性感染
Unveiling a New Perspective on Distinguishing Omicron Breakthrough Cases and Postimmune COVID-19-Naive Individuals: Insights from Antibody Profiles.
揭示区分奥密克戎突破病例和免疫后 COVID-19 初筛个体的新视角：抗体特征的见解。
Microbiol Spectr. 2023 Aug 17;11(4):e0180823. doi: 10.1128/spectrum.01808-23. Epub 2023 Jul 11.
4
Host immune responses in aged rhesus macaques against BBV152, an inactivated SARS-CoV-2 vaccine, and cross-neutralization with beta and delta variants.衰老恒河猴针对 BBV152（一种灭活的 SARS-CoV-2 疫苗）的宿主免疫反应，以及与β和δ变异株的交叉中和作用。
Front Immunol. 2023 Apr 28;14:1161571. doi: 10.3389/fimmu.2023.1161571. eCollection 2023.
5
An update on SARS-CoV-2 immunization and future directions.新型冠状病毒2型免疫接种的最新情况及未来方向。
Front Pharmacol. 2023 Mar 9;14:1125305. doi: 10.3389/fphar.2023.1125305. eCollection 2023.
6
Application of Traditional Vaccine Development Strategies to SARS-CoV-2.传统疫苗开发策略在 SARS-CoV-2 中的应用。
mSystems. 2023 Apr 27;8(2):e0092722. doi: 10.1128/msystems.00927-22. Epub 2023 Mar 2.
7
Identification of severe acute respiratory syndrome coronavirus 2 breakthrough infections by anti-nucleocapsid antibody among fully vaccinated non-healthcare workers during the transition from the delta to omicron wave.在从德尔塔毒株流行期过渡到奥密克戎毒株流行期期间，通过抗核衣壳抗体在完全接种疫苗的非医护人员中识别严重急性呼吸综合征冠状病毒2突破性感染情况。
Front Med (Lausanne). 2022 Nov 29;9:1019490. doi: 10.3389/fmed.2022.1019490. eCollection 2022.
8
Evaluation of immunoprotection against coronavirus disease 2019: Novel variants, vaccine inoculation, and complications.2019冠状病毒病免疫保护评估：新变种、疫苗接种及并发症
J Pharm Anal. 2023 Jan;13(1):1-10. doi: 10.1016/j.jpha.2022.10.003. Epub 2022 Oct 27.
9
Protective efficacy of COVAXIN® against Delta and Omicron variants in hamster model.COVAXIN®在仓鼠模型中对Delta和Omicron变体的保护效力。
iScience. 2022 Oct 21;25(10):105178. doi: 10.1016/j.isci.2022.105178. Epub 2022 Sep 22.
10
Application of Traditional Vaccine Development Strategies to SARS-CoV-2.传统疫苗研发策略在严重急性呼吸综合征冠状病毒2（SARS-CoV-2）上的应用
ArXiv. 2023 Jan 23:arXiv:2208.08907v2.
J Infect. 2022 Apr;84(4):e13-e15. doi: 10.1016/j.jinf.2022.01.044. Epub 2022 Feb 3.
4
SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses.严重急性呼吸综合征冠状病毒2型奥密克戎变异株B.1.1.529可导致广泛的中和抗体反应逃逸。
Cell. 2022 Feb 3;185(3):467-484.e15. doi: 10.1016/j.cell.2021.12.046. Epub 2022 Jan 4.
5
SARS-CoV-2 Omicron Variant Neutralization in Serum from Vaccinated and Convalescent Persons.接种疫苗者和康复者血清中对严重急性呼吸综合征冠状病毒2奥密克戎变种的中和作用
N Engl J Med. 2022 Feb 17;386(7):698-700. doi: 10.1056/NEJMc2119236. Epub 2022 Jan 12.
6
Regular and booster vaccination with inactivated vaccines enhance the neutralizing activity against Omicron variant both in the breakthrough infections and vaccinees.使用灭活疫苗进行常规和加强接种可增强突破性感染患者和接种疫苗者对奥密克戎变种的中和活性。
J Infect. 2022 Apr;84(4):579-613. doi: 10.1016/j.jinf.2022.01.004. Epub 2022 Jan 10.
7
Activity of convalescent and vaccine serum against SARS-CoV-2 Omicron.恢复期和疫苗血清对 SARS-CoV-2 奥密克戎变体的活性。
Nature. 2022 Feb;602(7898):682-688. doi: 10.1038/s41586-022-04399-5. Epub 2021 Dec 31.
8
Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial.灭活新冠病毒疫苗BBV152的安全性和免疫原性：一项双盲、随机、多中心2期试验的中期结果以及一项双盲、随机1期试验的3个月随访
Lancet Infect Dis. 2021 Jul;21(7):950-961. doi: 10.1016/S1473-3099(21)00070-0. Epub 2021 Mar 8.
9
Neutralizing antibody responses to SARS-CoV-2 in COVID-19 patients.COVID-19 患者体内针对 SARS-CoV-2 的中和抗体反应。
Indian J Med Res. 2020;152(1 & 2):82-87. doi: 10.4103/ijmr.IJMR_2382_20.